Amgen Inc ((AMGN)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Amgen Inc. is currently conducting a clinical study titled ‘A Phase 1b/2 Study Evaluating the Safety, Tolerability, Efficacy, and Pharmacokinetics of Bemarituzumab in Combination With Other Anti-cancer Therapies in Subjects With Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer (FORTITUDE-103).’ The study aims to assess the safety and effectiveness of bemarituzumab when used alongside other cancer treatments, specifically focusing on its combination with S-1, oxaliplatin, and nivolumab. This research is significant as it explores potential new treatment avenues for advanced gastric cancer, a condition with limited therapeutic options.
The interventions being tested include bemarituzumab, a drug administered via intravenous infusion, combined with other treatments such as CAPOX (a mix of oxaliplatin and capecitabine), SOX (a mix of oxaliplatin and S-1), and nivolumab, also given intravenously. These combinations aim to enhance the therapeutic effects against cancer cells.
The study follows an interventional design with a non-randomized, sequential intervention model. There is no masking involved, meaning both the researchers and participants know the treatments being administered. The primary purpose of the study is basic science, focusing on understanding the treatment’s effects.
The study began on May 17, 2022, with the primary completion and estimated completion dates not yet specified. The last update was submitted on August 20, 2025. These dates are crucial for tracking the study’s progress and anticipating when results might be available.
This update from Amgen could influence the company’s stock performance and investor sentiment positively, as successful outcomes might lead to new treatment approvals, enhancing Amgen’s market position. Competitors in the oncology sector may also be impacted as new therapies could shift market dynamics.
The study is ongoing, and further details can be accessed on the ClinicalTrials portal.